(19)
(11) EP 2 073 789 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
14.09.2022 Bulletin 2022/37

(45) Mention of the grant of the patent:
22.05.2019 Bulletin 2019/21

(21) Application number: 07870768.4

(22) Date of filing: 03.10.2007
(51) International Patent Classification (IPC): 
A61K 9/00(2006.01)
A61K 38/29(2006.01)
 A61K 9/08(2006.01)
A61P 19/10(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0019; A61K 9/08; A61K 38/29; A61P 19/00; A61P 19/08; A61P 19/10; A61P 31/04
(86) International application number:
PCT/US2007/021216
(87) International publication number:
WO 2008/063279 (29.05.2008 Gazette 2008/22)

(54)

A STABLE COMPOSITION COMPRISING A BONE ANABOLIC PROTEIN, NAMELY A PTHRP ANALOGUE, AND USES THEREOF

STABILE ZUSAMMENSETZUNG MIT ANABOLISCHEM KNOCHENPROTEIN, UND ZWAR EINEM PTHRP-ANALOGON, SOWIE DEREN VERWENDUNG

COMPOSITION STABLE D'UNE PROTÉINE ANABOLIQUE OSSEUSE QUI EST UN ANALOGUE DE PTHRP, ET SES EMPLOIS

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: 03.10.2006 US 848960 P

(43) Date of publication of application:
01.07.2009 Bulletin 2009/27

(60) Divisional application:
15176548.4 / 2957278

(73) Proprietors:
  • Radius Health, Inc.
    Waltham, MA 02451 (US)
  • IPSEN PHARMA S.A.S.
    92100 Boulogne-Billancourt (FR)

(72) Inventors:
  • DEY, Michael J.
    Cheshire CW11 1EW (GB)
  • MONDOLY, Nathalie
    78150 Le Chesnay (FR)
  • RIGAUD, Benedicte
    28260 Oulins (FR)
  • HENDERSON, Bart
    Belmont, MA 02478 (US)
  • LYTTLE, C. Richard
    Bala Cynwyd, PA 19004 (US)
  • ZHENGXIN, Dong
    Holliston, MA 01746 (US)

(74) Representative: Potter Clarkson 
The Belgrave Centre Talbot Street
Nottingham NG1 5GG
Nottingham NG1 5GG (GB)


(56) References cited: : 
WO-A-03/105772
 US-A1- 2005 282 749
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).